InSphero AG

https://www.insphero.com

InSphero is the pioneer of industrial-grade, 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology. Through partnerships, InSphero supports pharmaceutical and biotechnology researchers in successful decision-making by accurately rebuilding the human physiology in vitro. Its robust and precisely engineered suite of 3D InSight™ human tissue platforms are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. The company specializes in liver toxicology, metabolic diseases (e.g., T1 & T2 diabetes and NAFLD & NASH liver disease), and oncology (with a focus on immuno-oncology and PDX models). The scalable Akura™ technology underlying the company’s 3D InSight™ Discovery and Safety Platforms includes 96 and 384-well plate formats and the Akura™ Flow organ-on-a-chip system to drive efficient innovation throughout all phases of drug development. *

	Start	2009-01-01 splitoff
	Group	InSphero (Group)
	Predecessor	ETH Zürich, Dept. of Biosystems Science and Engineering (D-BSSE, Basel)
	Industry	cell-based assay (research)
	Person	Lichtenberg, Jan (InSphero 201401 CEO + Co-founder)
	Person 2	Strube, Randy (InSphero 201401– Director of Global Marketing)

	Region	Schlieren ZH
	Country	Switzerland
	Street	27 Wagistr.
	City	8952 Schlieren ZH
	Tel	+41-44-515049-0
		Address record changed: 2024-01-05

Basic data	Employees	A: 1 to 10 (2011-04-28)

		* Document for »About Section«: InSphero AG. (1/19/23). "Press Release: Brenus Pharma and InSphero Receive €1.5 Million in Grants from the European EUROSTARS Fund". Lyon & Schlieren.

		Record changed: 2023-12-20